Stroke

A recent study has found the long-term risk of developing thromboembolism with postoperative atrial fibrillation was similar to that of nonsurgical, nonvalvular atrial fibrillation.

A Q&A with Brett Carroll, MD, director of Vascular Medicine at Beth Israel Deaconess Medical Center, as he discusses stroke management, DOACs, and warfarin.

Investigators from the University of Duke School of Medicine compared results of the PROSPER Study and found results supporting the use of DOACs over warfarin in older patients following ischemic stroke.

An analysis that included data on more than 50,000 patients found that multiple metrics of warfarin control were individuals associated with subsequent bleeding.

Dalteparin sodium injection was shown to result in VTE resolution in a majority of treated patients from a clinical trial.

Patients treated with dabigatran following myocardial injury after noncardiac surgery were 20% less likely to die of a cardiovascular cause.

The Computed Tomography Angiography device from iSchemaView gives physicians quick, and diverse, options to analyze stroke patient candidates.

A large retrospective analysis from Canada suggests that dabigatran is about as safe and effective as warfarin in elderly patients with atrial fibrillation.

The relationship between a blood thinner and the body's natural defense against HIV was discussed in new research published in the Journal of the American Chemical Society.

Mitigating the risk of stroke, heart failure, and death when treating patients with atrial fibrillation requires a careful consideration of patient characteristics and management options.

Changes to the recommended use of various medications and catheter ablations rank among the highlights of comprehensive new guidelines for the treatment of patients with atrial fibrillation.

This podcast reviews key information about the safe storage, handling, and dispensing of Pradaxa (dabigatran etexilate mesylate) capsules.

We conducted a substudy of the Rate Control Versus Electrical Cardioversion (RACE) study to evaluate cardiovascular morbidity, mortality, and the outcome of rate and rhythm control treatment in subjects with and without hypertension with persistent atrial fibrillation.